Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
51 hedge funds and large institutions have $54.8M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less funds holding
Funds holding: 64 → 51 (-13)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
35% less capital invested
Capital invested by funds: $84M → $54.8M (-$29.2M)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
76% less call options, than puts
Call options by funds: $4K | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$1.53M |
| 2 |
RA
Royce & Associates
New York
|
+$452K |
| 3 |
ECM
Element Capital Management
New York
|
+$411K |
| 4 |
Millennium Management
New York
|
+$384K |
| 5 |
HP
Hikari Power
Tokyo,
Japan
|
+$383K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.25M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.96M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$895K |
| 4 |
Renaissance Technologies
New York
|
-$854K |
| 5 |
State Street
Boston,
Massachusetts
|
-$762K |
MRTX Hedge Fund Activity: Q2 2017 in Review
51 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2017, worth a combined $54.8M — down 35% from $84M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MRTX and 11 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was Broadfin Capital, adding an estimated $1.53M. The largest seller was BlackRock, cutting an estimated $2.25M.
- 51 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2017, down from 64 in Q1 2017.
- Funds reported $54.8M of Mirati Therapeutics, Inc. Common Stock stock for Q2 2017, down 35% quarter-over-quarter.
- 11 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2017 and 23 closed out, a net change of -12 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2017 was Broadfin Capital, an estimated $1.53M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2017 was BlackRock, an estimated $2.25M sold.
Based on aggregated 13F filings for Q2 2017.